NORMAL SITUATION

MEDVIA

Company — Normal situation.

Financial year 2024 · Closed on 31/12/2024

Net result-212,7 k €-152,5 %over 1 year
Gross margin770,4 k €-13,3 %over 1 year
Equity459,4 k €-31,6 %over 1 year
Workforce8,4 ETP+90,9 %over 1 year

Identity

Source · BCE/KBO

MEDVIA is a company registered in Belgium. It employs on average 8,4 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0772.406.446
Legal form
Non-profit organization
Latest accounts
31/12/2024
Average workforce
8,4 ETP
Signals
Solid equityGood liquidityHealthy social debts

Financials

Source · NBB, 3 filings

Trend over 3 financial years

202420232022
Income statement
Gross margin770,4 k €888,2 k €477,9 k €
EBITDA-180,5 k €411,2 k €268,2 k €
Operating result-197 k €408,8 k €268,2 k €
Net result-212,7 k €404,8 k €267,3 k €
Balance sheet
Equity459,4 k €672,2 k €267,3 k €
Total assets1,3 M €2,6 M €539,6 k €
Cash380,1 k €159,6 k €234,4 k €
Debts570,7 k €379,4 k €137,5 k €
Other
Workforce8,4 ETP4,4 ETP1,7 ETP

Board of directors

Source · NBB, accounts to 31/12/2024

12 active · 12 ended

Active mandates

Antleron

Director · 0505.975.160

Active
Cochlear Technology Centre Belgium

Director · 0863.920.305

Active
COMATE

Director · 0827.793.149

Active
FLANDERSBIO

Director · 0863.763.620

Active
Active
Janssen Pharmaceutica

Director · 0403.834.160

Active
Katholieke Universiteit te Leuven

Director · 0419.052.173

Active
Lakefront Biotherapeutics

Director · 0466.460.429

Active
MoveUP

Director · 0643.795.235

Active
Universiteit Gent

Director · 0248.015.142

Active
Vrije Universiteit Brussel

Director · 0449.012.406

Active

Ended mandates

Antleron

Mandate · 0505.975.160

Ended
Cochlear Technology Centre Belgium

Mandate · 0863.920.305

Ended
COMATE

Mandate · 0827.793.149

Ended
FLANDERSBIO

Mandate · 0863.763.620

Ended

Full financial information

Source · NBB
202420232022
Type of accountAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202401/01/202309/08/2021
Closing of the financial year31/12/202431/12/202331/12/2022
Length of the financial year12 months12 months17 months
Filing date10/06/202518/07/202401/08/2023
General meeting27/05/202523/04/202417/05/2023
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 3 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202427/05/202510/06/2025DutchPDF
Abridged model31/12/202323/04/202418/07/2024DutchPDF
Abridged model31/12/202217/05/202301/08/2023DutchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2024

12 active · 12 ended

Active mandates

Antleron

Director · 0505.975.160

Active
Cochlear Technology Centre Belgium

Director · 0863.920.305

Active
COMATE

Director · 0827.793.149

Active
FLANDERSBIO

Director · 0863.763.620

Active
Active
Janssen Pharmaceutica

Director · 0403.834.160

Active
Katholieke Universiteit te Leuven

Director · 0419.052.173

Active
Lakefront Biotherapeutics

Director · 0466.460.429

Active
MoveUP

Director · 0643.795.235

Active
Universiteit Gent

Director · 0248.015.142

Active
Vrije Universiteit Brussel

Director · 0449.012.406

Active

Ended mandates

Antleron

Mandate · 0505.975.160

Ended
Cochlear Technology Centre Belgium

Mandate · 0863.920.305

Ended
COMATE

Mandate · 0827.793.149

Ended
FLANDERSBIO

Mandate · 0863.763.620

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Restructuring17/02/2025
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Mandates03/10/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates21/05/2024
    MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates29/09/2022
    BENAMING - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Registered office14/06/2022
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Mandates11/04/2022
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Other11/08/2021
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024-212,7 k €↓
  2. 2023
    Annual accounts 2023404,8 k €↑
  3. 2022
    Annual accounts 2022267,3 k €